574625

Suramin sodium salt

≥98% (HPLC), crystalline solid, P2Y antagonist, Calbiochem^®

• Synonim(y): Suramin, Sodium Salt, P2Y Antagonist I, Purinergic Receptor P2Y Antagonist I, PTP Inhibitor VI, PTP Inhibitor VI, Purinergic Receptor P2Y Antagonist I, P2Y Antagonist I
• Wzór empiryczny (zapis Hilla): C₅₁H₃₄N₆O₂₃S₆ · 6Na
• Numer CAS: 129-46-4
• Masa cząsteczkowa: 1429.17
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD00210217
• Assay: ≥98% (HPLC)
• Form: crystalline solid
• Storage condition: OK to freeze, desiccated (hygroscopic)

Właściwości

• Nazwa produktu: Suramin, Sodium Salt, A reversible and competitive inhibitor of protein tyrosine phosphatases.
• Quality Segment: 100
• description: Merck USA index - 14, 9006
• assay: ≥98% (HPLC)
• form: crystalline solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, desiccated (hygroscopic)
• color: white
• solubility: water: 5 mg/mL
• shipped in: ambient
• storage temp.: 2-8°C
• SMILES string: [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[S](=O)(=O)([O-])c1cc2c(c(c1)[S](=O)(=O)O)c(ccc2[S](=O)(=O)O)\N=C(/[O-])\c3cc(c(cc3)C)\N=C(/[O-])\c4cc(ccc4)\N=C(\Nc5cc(ccc5)\C(=N\c6c(ccc(c6)\C(=N\c7c8c(c(cc7)[S](=O)(=O)O)cc(cc8[S](=O)(=O)O)[S](=O)(=O)O)\[O-])C)\[O-])
• InChI: 1S/C51H40N6O23S6.6Na/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80;;;;;;/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80);;;;;;/q;6*+1/p-6
• InChI key: VAPNKLKDKUDFHK-UHFFFAOYSA-H

Opis

General description

A reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of G_α-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca²⁺-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC₅₀ = 15 µM). Reported to interact with ATP-binding enzymes and P₂-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids.

An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerase I and II. Inhibits Ca²⁺-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC₅₀ = 15 µM). Reported to interact with ATP-binding enzymes and P₂-purinergic receptors. An effective inhibitor of angiogenesis in calmodulin assays when given in combination with angiostatic steroids.

Biochem/physiol Actions

Cell permeable: no

Primary Target
protein tyrosine phosphatases

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: 15 µM against phospholipase D

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.

Other Notes

Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
Denhertog, A., et al. 1992. J. Physiol.454, 591.
Nakajima, M., et al. 1991. J. Biol. Chem.266, 9661.
Wilks, J.W., et al. 1991. Int. J. Radiat. Biol.60, 73.
Huang, R.C., et al. 1990. Mol. Pharmacol.37, 304.
Kopp, R. and Pfeiffer, A. 1990. Cancer Res.50, 6490.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable